All Stories

  1. Clinical implementation of preemptive pharmacogenomics in psychiatry
  2. Data-Driven Drug Repurposing in Diabetes Mellitus through an Enhanced Knowledge Graph
  3. Cloudscreen: A “one-stop-shop” Platform for Drug Repurposing
  4. A quest for the stereo-electronic requirements for selective agonism for the neurotrophin receptors TrkA and TrkB in 17-spirocyclic-dehydroepiandrosterone derivatives
  5. A Robust Machine Learning Framework Built Upon Molecular Representations Predicts CYP450 Inhibition: Toward Precision in Drug Repurposing
  6. Bioenergetic Profiling in Glioblastoma Multiforme Patients with Different Clinical Outcomes
  7. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study
  8. Development and Comparative In Vitro and In Vivo Study of BNN27 Mucoadhesive Liposomes and Nanoemulsions for Nose-to-Brain Delivery
  9. CAR Exosome-Based Therapeutics
  10. Pharmacometabolomics-Based Translational Biomarkers: How to Navigate the Data Ocean
  11. Untargeted Metabolomics for Disease-Specific Signatures
  12. Radiotherapy in Metastatic Urothelial Carcinoma: Rationale and Clinical Applications
  13. Diagnostic and Therapeutic Challenges in a Patient with Ureteral Metastases from a Triple Negative Breast Cancer
  14. A 3-miRNA Signature Enables Risk Stratification in Glioblastoma Multiforme Patients with Different Clinical Outcomes
  15. The clinical utility of polygenic risk scores in genomic medicine practices: a systematic review
  16. ENT-A010, a Novel Steroid Derivative, Displays Neuroprotective Functions and Modulates Microglial Responses
  17. Development and Biological Characterization of a Novel Selective TrkA Agonist with Neuroprotective Properties against Amyloid Toxicity
  18. Three-Dimensional Cell Metabolomics Deciphers the Anti-Angiogenic Properties of the Radioprotectant Amifostine
  19. Exploiting the Role of Hypoxia-Inducible Factor 1 and Pseudohypoxia in the Myelodysplastic Syndrome Pathophysiology
  20. Bioenergetic Profiling of the Differentiating Human MDS Myeloid Lineage with Low and High Bone Marrow Blast Counts
  21. Clinical implementation of preemptive pharmacogenomics in psychiatry: Τhe “PREPARE” study
  22. The role of microRNAs in gliomas – Therapeutic implications
  23. VEGF-A and ICAM-1 Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer
  24. Pharmacomicrobiomics informs clinical pharmacogenomics
  25. A Noninvasive Ocular (Tear) Sampling Method for Genetic Ascertainment of Transgenic Mice and Research Ethics Innovation
  26. New molecular diagnostic trends and biomarkers for amyotrophic lateral sclerosis
  27. Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention
  28. Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in β-Thalassemia Intermedia: A Validation Cohort Study
  29. Implementation of Genomic Medicine
  30. How far have we come with contextual data integration in drug discovery?
  31. Variants in TPMT, ITPA, ABCC4 And ABCB1 Genes as Predictors of 6-Mercaptopurine Induced Toxicity in Children with Acute Lymphoblastic Leukemia
  32. An Exploratory Study of Radiation Dermatitis in Breast Cancer Patients
  33. The New Age of -omics in Urothelial Cancer – Re-wording Its Diagnosis and Treatment
  34. Recent trends on the role of epigenomics, metabolomics and noncoding RNAs in rationalizing mood stabilizing treatment
  35. Searching for Clinically Relevant Biomarkers in Geriatric Oncology
  36. Multi-Omics for Biomarker Discovery and Target Validation in Biofluids for Amyotrophic Lateral Sclerosis Diagnosis
  37. Proteomics and Metabolomics Data Analysis for Translational Medicine
  38. A Review of Tools to Automatically Infer Chromosomal Positions From dbSNP and HGVS Genetic Variants
  39. Economic Evaluation and Cost-Effectiveness Analysis of Genomic Medicine Interventions in Developing and Emerging Countries
  40. Human Genomic Databases in Translational Medicine
  41. Translating Genomic Information to Rationalize Drug Use
  42. Advancing Global Precision Medicine: An Overview of Genomic Testing and Counseling Services in Malaysia
  43. Genomic variants in the FTO gene are associated with sporadic amyotrophic lateral sclerosis in Greek patients
  44. Genomic Medicine Without Borders: Which Strategies Should Developing Countries Employ to Invest in Precision Medicine? A New “Fast-Second Winner” Strategy
  45. Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β-type hemoglobinopathy patients
  46. Cancer Genomics and Public Health
  47. Sensitive Monogenic Noninvasive Prenatal Diagnosis by Targeted Haplotyping
  48. Exploring public genomics data for population pharmacogenomics
  49. Pharmacometabolomics Informs Quantitative Radiomics for Glioblastoma Diagnostic Innovation
  50. Key Pharmacogenomic Considerations for Sickle Cell Disease Patients
  51. Editorial: (Pharmaco)Metabolomics in Drug Discovery and Individualisation of Treatment
  52. Correction: A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics
  53. Genomic Medicine in Developing Countries and Resource-Limited Environments
  54. Genomic Databases
  55. Perspectives for Future DNA Sequencing Techniques and Applications
  56. Cancer Genomics and Public Health
  57. Application of the DruGeVar Database in Cancer Genomics and Pharmacogenomics
  58. Exosomes: A Cancer Theranostics Road Map
  59. Pharmacogenomics in Clinical Care and Drug Discovery
  60. Low- and Medium-Throughput Variant Detection Methods
  61. Pharmacogenomics education and research at the Department of Pharmacy, University of Patras, Greece
  62. Correlation of SIN3A genomic variants with β-hemoglobinopathies disease severity and hydroxyurea treatment efficacy
  63. Pharmacometabolomics Informs Viromics toward Precision Medicine
  64. Novel genetic risk variants for pediatric celiac disease
  65. Expanded national database collection and data coverage in the FINDbase worldwide database for clinically relevant genomic variation allele frequencies
  66. A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics
  67. ePGA: A Web-Based Information System for Translational Pharmacogenomics
  68. Development and validation of a UHPLC-UV method for the determination of a prostate secretory protein 94-derived synthetic peptide (PCK3145) in human plasma and assessment of its stability in human plasma
  69. Pharmacometabolomics-aided Pharmacogenomics in Autoimmune Disease
  70. Genomic variants in the ASS1 gene, involved in the nitric oxide biosynthesis and signaling pathway, predict hydroxyurea treatment efficacy in compound sickle cell disease/β-thalassemia patients
  71. Nutrigenomics 2.0: The Need for Ongoing andIndependentEvaluation and Synthesis of Commercial Nutrigenomics Tests' Scientific Knowledge Base for Responsible Innovation
  72. Allele and genotype frequencies of the two single nucleotide polymorphisms in the VKORC1 gene that are most important for warfarin treatment among Emiratis
  73. Computational approaches in target identification and drug discovery
  74. Pharmacometabolomics: Applications and Challenges
  75. Functional Analysis of anAγ-Globin Gene Promoter Variant (HBG1: g.-225_-222delAGCA) Underlines Its Role in Increasing Fetal Hemoglobin Levels Under Erythropoietic Stress
  76. Enabling pharmacogenomic services: Informatics and computational discovery aspects
  77. Identification of a novel homozygous SPG7 mutation by whole exome sequencing in a Greek family with a complicated form of hereditary spastic paraplegia
  78. TPMT gene expression is increased during maintenance therapy in childhood acute lymphoblastic leukemia patients in a TPMT gene promoter variable number of tandem repeat-dependent manner
  79. Drug-Induced Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Call for Optimum Patient Stratification and Theranostics via Pharmacogenomics
  80. As solid scientific evidence is lacking, available nutrigenomics tests cannot be recommended
  81. The Implications of Metabotypes for Rationalizing Therapeutics in Infants and Children
  82. Identification of cancer predisposition variants in apparently healthy individuals using a next-generation sequencing-based family genomics approach
  83. Whole genome sequencing in pharmacogenomics
  84. Nutrigenomics: A controversy
  85. Pharmacogenomics for Haemoglobinopathies Therapeutics
  86. Circulating pEGFR Is a Candidate Response Biomarker of Cetuximab Therapy in Colorectal Cancer
  87. Deciphering next-generation pharmacogenomics: an information technology perspective
  88. Enhancing the Biological Relevance of Secretome-Based Proteomics by Linking Tumor Cell Proliferation and Protein Secretion
  89. Personalized pharmacogenomics profiling using whole-genome sequencing
  90. Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients
  91. Assessment of the Pharmacogenomics Educational Environment in Southeast Europe
  92. DruGeVar: An Online Resource Triangulating Drugs with Genes and Genomic Biomarkers for Clinical Pharmacogenomics
  93. Ovarian malignant ascites-derived lymphocytes stimulated with prothymosin α or its immunoactive decapeptide lyse autologous tumour cells in vitro and retard tumour growth in SCID mice
  94. Rationally designed cyclic analogues of luteinizing hormone-releasing hormone: Enhanced enzymatic stability and biological properties
  95. 1077 Ovarian Malignant Ascites-derived Lymphocytes Stimulated With Prothymosin Alpha or Its Immunoactive Decapeptide Lyse Autologous Tumor Cells in Vitro and Retard Tumor Growth in SCID Mice
  96. Peptide and protein drugs: The study of their metabolism and catabolism by mass spectrometry
  97. Evaluation of a Stable Gonadotropin-Releasing Hormone Analog in Mice for the Treatment of Endocrine Disorders and Prostate Cancer
  98. Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis
  99. Simultaneous Absolute Quantification of the Glucose-Dependent Insulinotropic Polypeptides GIP1−42and GIP3−42in Mouse Plasma by LC/ESI-MS/MS: Preclinical Evaluation of DP-IV Inhibitors
  100. In vivoevaluation andin vitrometabolism of leuprolide in mice-mass spectrometry-based biomarker measurement for efficacy and toxicity
  101. Evaluation of gonadotropin-releasing hormone analogues in mice – pharmacokinetic studies and biomarker based efficacy by mass spetrometry